Traders Sell Shares of Gilead Sciences, Inc. (GILD) on Strength (GILD)
Investors sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading on Thursday. $514.94 million flowed into the stock on the tick-up and $634.60 million flowed out of the stock on the tick-down, for a money net flow of $119.66 million out of the stock. Of all stocks tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $2.48 for the day and closed at $83.71
A number of research analysts recently issued reports on the stock. Jefferies Group LLC restated a “hold” rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 11th. Vetr cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price target for the company. in a report on Monday. BMO Capital Markets reiterated an “outperform” rating and issued a $82.00 price target (up previously from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Finally, Berenberg Bank reiterated a “buy” rating and issued a $86.00 price target (up previously from $79.00) on shares of Gilead Sciences in a report on Sunday, August 20th. Twelve research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $82.26.
The company has a 50 day moving average of $74.38 and a 200 day moving average of $69.29. The company has a market capitalization of $109.37 billion, a P/E ratio of 9.10 and a beta of 1.18.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.08 earnings per share. On average, analysts expect that Gilead Sciences, Inc. will post $8.73 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.48%. Gilead Sciences’s dividend payout ratio is presently 22.58%.
In related news, EVP Gregg H. Alton sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the completion of the transaction, the executive vice president now owns 113,237 shares in the company, valued at $8,945,723. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 256,666 shares of company stock valued at $19,173,184. 1.30% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of GILD. Intl Fcstone Inc. purchased a new position in Gilead Sciences during the second quarter worth about $1,110,000. Griffin Asset Management Inc. purchased a new position in Gilead Sciences during the second quarter worth about $1,151,000. Gs Investments Inc. purchased a new position in Gilead Sciences during the second quarter worth about $577,000. Paradigm Financial Advisors LLC increased its position in Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 26 shares during the period. Finally, RNC Capital Management LLC increased its position in Gilead Sciences by 1.4% in the second quarter. RNC Capital Management LLC now owns 83,702 shares of the biopharmaceutical company’s stock worth $5,924,000 after buying an additional 1,185 shares during the period. Institutional investors and hedge funds own 74.04% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/02/traders-sell-shares-of-gilead-sciences-inc-gild-on-strength-gild-6.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.